Dezamizumab

DB15153InvestigationalProtein Based Therapies

Dezamizumab is under investigation in clinical trial NCT03417830 (Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging).

Mechanism
Curator reviewed
Also known as
ANTI - SAP MAB · IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS APCS (AMYLOID P COMPONENT SERUM, SERUM AMYLOID P COMPONENT, SAP, PENTRAXIN-2, PTX2)), HUMANIZED MONOCLONAL ANTIBODY · IMMUNOGLOBULIN G1, ANTI-(SERUM AMYLOID P PROTEIN) (HUMAN-MUS MUSCULUS MONOCLONAL GSK2398852 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL GSK2398852 LIGHT CHAIN, DIMER · recombinant monoclonal antibody to human serum amyloid P component
Code names
GSK-2398852

Resolves to

Compound
UNII6U3F28IT58CAS1662664-56-3
Targets
P02743APCS

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Dezamizumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In